Monoclonal antibodies

Biotechnology company Tiziana Life Sciences is initiating a programme to develop intranasal foralumab for the treatment or prevention of type 1 diabetes. “With the FDA approval of the humanised anti-CD3 mAb TZIELD (teplizumab-mzwv injection) and then its subsequent announced acquisition of Provention Bio by Sanofi for $2.9 billion, CD3 has emerged as an established and […]

This report will:   Provide an overview of the monoclonal antibody (mAbs) industry: market value, key on the future of antibody-based drug players, opportunities and the future  Explore what’s next for antibody-based drugs and where the opportunity is coming from  Include an interview Bio-Rad’s John Cardone, who shares expertise on the future of antibody-based drug discovery   […]

Created by DDW and sponsored by Bio-Rad, The future of antibody-based drugs: Where are the opportunities and what does the future hold? is a free In Focus report, available here.  This report will:   Provide an overview of the monoclonal antibody (mAbs) industry: market value, key on the future of antibody-based drug players, opportunities and the future  […]

Gohibic (vilobelimab) has been granted an Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for the treatment of Covid-19 in hospitalised adults. The monoclonal anti-human complement factor C5a antibody should be initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). Professor Niels C Riedemann, CEO […]

The first subjects have been dosed in a Phase I clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein (LDL) cholesterol, a known factor in heart disease. The drug works by targeting proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9). “We’re excited to get this first-in-human trial of VXX-401 started. The concept […]

Purple Biotech has revealed positive new results from exploratory analyses conducted as part of a Phase I dose escalation study into CM24 plus nivolumab for advanced cancer. The study enrolled 14 patients with advanced cancers including 11 patients with pancreatic adenocarcinoma (PDAC), two patients with colorectal adenocarcinoma (CRC) and one patient with papillary thyroid cancer. […]

Leqembi’s prospects in the Alzheimer’s disease market remain uncertain despite its advantages over Aduhelm, says analytics company GlobalData.  Eisai and Biogen’s anti-amyloid beta (Aβ) monoclonal antibody (mAb), Leqembi (lecanemab), recently gained approval from the Food and Drug Administration (FDA) under the accelerated approval pathway for the treatment of Alzheimer’s disease (AD) in patients with early […]

This article is sponsored by Cytiva. The new PrismA ELISA kit is an enzyme-linked immunosorbent assay designed to measure residual ligand leakage when using MabSelect PrismA chromatography resin and Fibro PrismA chromatography adsorbers. The kit is used during the development and manufacture of monoclonal antibody (mAb) biopharmaceuticals.  This kit is the only commercial ELISA kit […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The drug discovery industry has hit the ground running in 2023 with some big announcements in the first week, particularly in cancer research, […]

News round-up for 2-6 January by DDW Digital Content Editor Diana Spencer. The drug discovery industry has hit the ground running in 2023 with some big announcements in the first week, particularly in cancer research, where there has been good news in pancreatic, urothelial and uveal cancers.  The top stories:  Accelerated development for Covid-19 monoclonal […]